Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple map may end painful insulin lumps for diabetes patients

NCT ID NCT07561086

Disease control Sponsor: Helwan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a visual injection site map to help people with diabetes rotate where they inject insulin. The goal was to reduce lipohypertrophy—lumpy fatty tissue caused by repeated shots in the same spot—and improve blood sugar control. 170 adults on insulin for at least six months took part, with half using the map and half getting standard verbal advice. Over six months, researchers checked for lumps, how well patients followed rotation, and changes in HbA1c and blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Insulin Injection Site Mapping Tool (behavioral intervention)
What this could lead to
If it works, this simple mapping tool could help people with diabetes avoid painful lumps and get more stable blood sugar from their insulin shots.
What could go wrong
This is a small, completed trial with 170 participants, so results may not apply to everyone. The tool is just a guide—it won't replace careful injection habits or medical advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

170 people

The number who actually took part.

Started

Jun 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years and older. * Diagnosed with Type 1 or Type 2 diabetes mellitus. * Currently receiving insulin therapy for a minimum of six months. * Capable of self-injecting insulin or receiving assistance with injections at least once daily. * Able and willing to provide informed consent to participate in the study. * Able to understand and follow the study protocols. Exclusion Criteria: * Presence of mental illnesses or severe cognitive impairment that may affect participation. * Individuals with skin disorders at injection sites (e.g., severe eczema, psoriasis, or infections) that could interfere with the evaluation of lipohypertrophy. * Women who are pregnant or lactating. * Participation in another interventional clinical trial within the past three months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lipohypertrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus lipodystrophy type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lipohypertrophy Type 1 diabetes mellitus

Contacts and locations

Locations

  • Matruh General Hospital

    Marsá Maţrūḩ, Mersa Matrouh, 51511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.